Literature DB >> 309437

Experimental murine candidiasis: pathological and immune responses in T-lymphocyte-depleted mice.

D K Giger, J E Domer, S A Moser, J T McQuitty.   

Abstract

Mice depleted of T-lymphocytes by thymectomy and irradiation (TXB) and immunologically competent mice were compared for gross and histological pathology as well as immune responses after cutaneous and/or intravenous challenge with Candida albicans. In response to a first cutaneous inoculation with viable Candida, TXB, sham-operated (SXB), and unmanipulated (normal) mice, all developed lesions of comparable size, duration, and histopathology. When challenged a second time cutaneously, normal and SXB mice developed lesions which were greatly increased in size when compared with those produced by a first cutaneous infection, whereas TXB mice developed lesions comparable in size to those initiated by the first infection. Histologically, the first and second lesions in all animals were acute abscesses predominantly comprised of polymorphonuclear leukocytes. The larger second lesions in SXB and normal mice were accompanied by detectable circulating antibody and by delayed hypersensitivity. Neither circulating antibody nor delayed hypersensitivity were stimulated in the TXB mice. When challenged intravenously, all previously uninfected mice, regardless of T-cell status, were equally susceptible to C. albicans. Contrary to SXB or normal mice, however, TXB mice which had been infected cutaneously were not more resistant to a subsequent intravenous challenge as judged by 6-week survival. The results suggest that T-cells do not play a significant role in innate resistance of mice to systemic candidiasis, but that such cells are important in the development of acquired resistance.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 309437      PMCID: PMC422059          DOI: 10.1128/iai.21.3.729-737.1978

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  32 in total

1.  The occurrence of opportunistic fungus infections in a cancer hospital.

Authors:  R V HUTER; H S COLLINS
Journal:  Lab Invest       Date:  1962-11       Impact factor: 5.662

2.  Maximum utilization of the life table method in analyzing survival.

Authors:  S J CUTLER; F EDERER
Journal:  J Chronic Dis       Date:  1958-12

3.  A study of Candida albicans agglutinins in human sera.

Authors:  H I WINNER
Journal:  J Hyg (Lond)       Date:  1955-12

Review 4.  The role of cell-mediated immunity in the induction of inflammatory responses. Parke-Davis Award Lecture, 1977.

Authors:  S Cohen
Journal:  Am J Pathol       Date:  1977-09       Impact factor: 4.307

5.  Enhanced primary resistance to Listeria monocytogenes in T cell-deprived mice.

Authors:  C Chan; P A Kongshavn; E Skamene
Journal:  Immunology       Date:  1977-04       Impact factor: 7.397

6.  Systemic fungal infections complicating renal transplantation and immunosuppressive therapy. Clinical, microbiologic, neurologic and pathologic features.

Authors:  D Rifkind; T L Marchioro; S A Schneck; R B Hill
Journal:  Am J Med       Date:  1967-07       Impact factor: 4.965

7.  Experimental murine candidiasis: cell-mediated immunity after cutaneous challenge.

Authors:  J E Domer; S A Moser
Journal:  Infect Immun       Date:  1978-04       Impact factor: 3.441

8.  Experimental murine candidiasis: pathological and immune responses to cutaneous inoculation with Candida albicans.

Authors:  D K Giger; J E Domer; J T McQuitty
Journal:  Infect Immun       Date:  1978-02       Impact factor: 3.441

9.  Immunity to experimental renal candidiasis in rats.

Authors:  T J Rogers; E Balish
Journal:  Infect Immun       Date:  1978-02       Impact factor: 3.441

10.  THE ROLE OF THE THYMUS IN RESISTANCE TO INFECTION AND ENDOTOXIN TOXICITY.

Authors:  S B SALVIN; R D PETERSON; R A GOOD
Journal:  J Lab Clin Med       Date:  1965-06
View more
  25 in total

1.  Effect of Friend leukemia virus infection on susceptibility to Candida albicans.

Authors:  M A Moors; S M Jones; K K Klyczek; T J Rogers; H R Buckley; K J Blank
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

2.  Evidence for macrophage-mediated protection against lethal Candida albicans infection.

Authors:  F Bistoni; A Vecchiarelli; E Cenci; P Puccetti; P Marconi; A Cassone
Journal:  Infect Immun       Date:  1986-02       Impact factor: 3.441

3.  Th1 and Th2 cytokine secretion patterns in murine candidiasis: association of Th1 responses with acquired resistance.

Authors:  L Romani; S Mocci; C Bietta; L Lanfaloni; P Puccetti; F Bistoni
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

4.  Immunity to Candida albicans.

Authors:  T J Rogers; E Balish
Journal:  Microbiol Rev       Date:  1980-12

5.  Immune response in mice infected with Candida albicans in the mycelial form.

Authors:  M E Bibas Bonet de Jorrat; G A de Valdez; S F de Petrino; A Sirena; G Perdigón
Journal:  Mycopathologia       Date:  1989-05       Impact factor: 2.574

6.  Pathological observations in experimental candida infection of sensitized guinea pigs.

Authors:  M Isoda
Journal:  Mycopathologia       Date:  1985-09       Impact factor: 2.574

7.  Lack of effect of Candida albicans mannan on development of protective immune responses in experimental murine candidiasis.

Authors:  R E Garner; J E Domer
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

8.  Inoculation candidiasis in a murine model of severe combined immunodeficiency syndrome.

Authors:  S Mahanty; R A Greenfield; W A Joyce; P W Kincade
Journal:  Infect Immun       Date:  1988-12       Impact factor: 3.441

9.  Mouse candidiasis. II. Host responses are T-cell dependent and regulated by genes in the major histocompatibility complex.

Authors:  R B Ashman
Journal:  Immunogenetics       Date:  1987       Impact factor: 2.846

10.  Immunoregulation in experimental murine candidiasis: specific suppression induced by Candida albicans cell wall glycoprotein.

Authors:  E W Carrow; J E Domer
Journal:  Infect Immun       Date:  1985-07       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.